An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
Clinical trial NCT07357597 · RECRUITING
Trial details
- NCT number
- NCT07357597
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-24
- Primary completion
- 2028-01-04
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.